BUFFALO, N.Y. – The University at Buffalo Center for
Advanced Biomedical and Bioengineering Technology (UB CAT), a
program of UB’s New York State Center of Excellence in
Bioinformatics and Life Sciences (CBLS), has awarded more than
$500,000 in funding to 16 life sciences companies.
Sponsored by the New York State Division of Science, Technology
and Innovation (NYSTAR), the UB CAT is one of 15 designated higher
education institutions in New York State dedicated to leveraging
university resources to drive company growth in technology-based
industry sectors. UB CAT is one of only three CATs focused on the
The companies receiving UB CAT support for the 2016-17 fiscal
- Abcombi Biosciences, a preclinical-stage biotechnology
company utilizing “smart” vaccines to redefine the
design of pneumococcal vaccines.
- Albany Molecular Research Inc. (AMRI), a global
contract research and manufacturing organization identifying novel
cancer therapeutics to support and expand its drug discovery
- Atomic Medical Innovations Inc., a surgical products and
medical device company creating a specialized foam product to help
combat enterocutaneous fistulas (ECFs).
- Cellular Preservation Technologies, uses xenon gas as a
preservative to increase the shelf life of cells.
- Efferent Labs, a preclinical-stage medical technology
company creating an implantable biosensor technology that uses
living cells to monitor human biology.
- Empirican PRN, a physician-directed clinical research
network dedicated to rapid, high quality patient enrollment.
- For-Robin Inc., an immunotherapy company that is
developing an antibody that attacks tumor cells.
- Heads Up Display Inc., a wearable technology company,
detects, indicates and records hazardous exposure in
life-threatening work environments.
- INVO Bioscience Inc., a medical device company that is
creating a biodegradable polymer for in vivo fertilization
- Medical Conservation Devices LLC, a medical device
company that is analyzing a new ventilator system to be used in
- ONY Inc., a biopharmaceutical company that uses an
artificial blood vessel to alleviate heart defects in infants.
- Photolitec LLC, a life sciences company using
photodynamic technology both surgically and therapeutically to
treat cancer patients.
- PostProcess Technologies LLC, an additive manufacturer
that cleans and modifies material surface properties on 3D printed
- Rheonix Inc., a molecular diagnostics company, creating
a powerful microfluidic platform that miniaturizes and automates
all the functions of a molecular biology lab on a disposable
- SynchroPET Inc., a biomedical device manufacturer with a
groundbreaking technology in the radiological PET scanner
- You First Services Inc., a research and development
company that is fabricating an enduring temporomandibular joint
(TMJ) with lubricated fibrous tissue to reduce wear.
In addition, Jeff Dunbar, director for UB’s Office of
Science, Technology Transfer and Economic Outreach (STOR), has been
named co-director of UB CAT with Norma Nowak, PhD, executive
director of the CBLS, who has served as director and principal
investigator of UB CAT since 2014.
“We are thrilled to have Jeff as co-director of the UB
CAT,” Nowak said. “He brings a wealth of industry
expertise and support to the center staff, life sciences companies
and university faculty.”
As director of STOR, Dunbar identifies, protects and
commercializes new technologies that stem from more than $150
million in annual UB research and development expenditures.
Dunbar is a former senior product manager and senior financial
analyst for Bristol-Myers Squibb Pharmaceuticals and worked in
production management and engineering for Dunlop Tire Corporation.
Dunbar holds a MBA with concentrations in marketing and finance and
a BS in industrial engineering, both from UB, and is a member of
the Association of University Technology Managers.
Under Nowak and Dunbar’s leadership, the UB CAT will
continue to assist the companies and university faculty and
maximize the outcomes of the projects, making a stronger impact on
the New York State economy and ecosystem.
Companies interested in learning more about UB CAT and the
application process may contact Natalie Weil at 716-888-4728 or email@example.com.